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A new allosteric site in glycogen phosphorylase b as a target for
drug interactions
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Nikos G Gavalas1 and Louise N Johnson2
Background: In muscle and liver, glycogen concentrations are regulated by the
coordinated activities of glycogen phosphorylase (GP) and glycogen synthase.
GP exists in two forms: the dephosphorylated low-activity form GPb and the
phosphorylated high-activity form GPa. In both forms, allosteric effectors can
promote equilibrium between a less active T state and a more active R state.
GP is a possible target for drugs that aim to prevent unwanted glycogen
breakdown and to stimulate glycogen synthesis in non-insulin-dependent
diabetes. As a result of a data bank search, 5-chloro-1H-indole-2-carboxylic
acid (1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)amide,
CP320626, was identified as a potent inhibitor of human liver GP. Structural
studies have been carried out in order to establish the mechanism of this
unusual inhibitor.
Results: The structure of the cocrystallised GPb–CP320626 complex has
been determined to 2.3 Å resolution. CP320626 binds at a site located at the
subunit interface in the region of the central cavity of the dimeric structure.
The site has not previously been observed to bind ligands and is some 15 Å
from the AMP allosteric site and 33 Å from the catalytic site. The contacts
between GPb and CP320626 comprise six hydrogen bonds and extensive
van der Waals interactions that create a tight binding site in the T-state
conformation of GPb. In the R-state conformation of GPa these interactions
are significantly diminished. 
Conclusions: CP320626 inhibits GPb by binding at a new allosteric site.
Although over 30 Å from the catalytic site, the inhibitor exerts its effects by
stabilising the T state at the expense of the R state and thereby shifting the
allosteric equilibrium between the two states. The new allosteric binding site
offers a further recognition site in the search for improved GP inhibitors.
Introduction
Non-insulin-dependent diabetes is characterised by ele-
vated blood glucose levels that arise from resistance to the
action of insulin and/or a deficiency in insulin secretion
[1,2]. Insulin promotes the deposition of glycogen in the
liver and triglyceride in adipose tissues, and also activates
glucose transport and glycogen synthesis in muscle. Type
2 diabetes is treated with diet, exercise, drugs that
promote insulin release from the β cells of the pancreas,
and with insulin. Such treatment is not always satisfactory,
especially in the control of extreme fluctuations in blood
glucose levels, and there is a continued search for new
compounds to treat this condition. Glycogen phosphory-
lase (GP; E.C.2.4.1.1) offers a potential target for such
compounds because of its essential roles in glycogen
metabolism and control of liver glucose output. 
GP catalyses the degradative phosphorolysis of glycogen to
glucose-1-phosphate (glucose-1-P). In muscle, glucose-1-P
is utilised via glycolysis to generate metabolic energy, but
in the liver it is mostly converted to glucose, which is
output for the benefit of other tissues [3]. Both in muscle
and liver, GP exists in two interconvertible forms: the
dephosphorylated form (GPb, low activity and low sub-
strate affinity) and the Ser14-phosphorylated form (GPa,
high activity and high substrate affinity). With both forms,
allosteric effectors can promote equilibrium between a less
active T state and a more active R state, the structures of
which have been characterised (reviewed in [4–6]). Insulin
stimulates muscle and liver cells to transport glucose out of
the blood stream and to store it within the cell in the form
of glycogen. In the liver, glucose itself assists the process of
switching the cell from glycogenolysis to glycogen synthe-
sis. Glucose is a competitive inhibitor of GPa and thus
decreases glycogenolysis [7]. It also promotes the less
active T state of GPa, which is a better substrate than the
R state for the inactivating enzyme protein phosphatase 1.
GPa, but not GPb, is a potent inhibitor of the phosphatase
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action on glycogen synthase and it is only when GP has
been dephosphorylated that the phosphatase is free to acti-
vate glycogen synthase [8,9].
These observations led to the search for glucose analogue
inhibitors that would promote the T state and allow mod-
ulation of glycogen metabolism. Crystallographic studies
with the rabbit muscle enzyme (which is over 80% homol-
ogous to the liver isoform) showed highly specific binding
of the glucose analogues at the catalytic site of GP and sta-
bilisation of the T state conformation. These inhibitors
were designed on the basis of information derived from
the X-ray crystal structure of T state rabbit muscle GPb
[10–15]. Compounds that were 1000 times more potent
than glucose were found that achieved the desired effects
in modulating GP activity in hepatic cells [16–18].
However, these compounds failed to stimulate glycogen
synthase activity in cells because of modification by phos-
phorylation in the cell; the phosphorylated compounds
failed to activate glycogen synthase [17,19]. Nevertheless,
the rationale for targeting GP through modulating its
allosteric properties has continued to be of interest. Com-
pounds unrelated to the physiological regulators of GP can
exert potent effects, for example, the compound Bay
W1807 (Ki = 1.6 nM) regulates activity through recogni-
tion at the AMP-binding site [20].
As part of a screening process to identify compounds that
might contribute to the regulation of glycogen metabo-
lism, CP91149 (Figure 1a) was discovered by high-
throughput screening of >300,000 compounds, from a
sample bank, against recombinant human liver GPa [21].
CP91149 was characterised in vitro and in vivo and shown
to be an inhibitor of human liver GPa with an IC50 of
1 µM. The compound acts synergistically with both
glucose (IC50 = 130 nM) and caffeine (IC50 = 140 nM)
when measured in the direction of glycogen synthesis,
suggesting that CP91149 is kinetically distinct from both
glucose and caffeine. Two series of compounds derived
from CP91149, 3-((indole-2-carbonyl)amino)-2-hydroxy-4-
phenyl-butyric acid and N-(indole-2-carbonyl)phenylala-
nine analogues, were also synthesised and assessed for
their ability to inhibit liver GPa and glycogenolysis [22].
The related compound CP320626 (Figure 1b), is a potent
inhibitor of human liver GPa (IC50 = 205 nM in the pres-
ence of glucose) and has been shown to produce marked
glucose lowering at 10 mg kg–1 in diabetic ob/ob mice,
without altering plasma insulin levels [22]. 
GP contains at least five potential regulatory sites: the
Ser14 phosphate-recognition site, the AMP activatory
and the glucose-6-P inhibitory allosteric sites, the cat-
alytic site that binds glycogen and glucose-1-P, the
inhibitor site located 12 Å from the catalytic site which
binds caffeine and related compounds, and the glycogen
storage site. CP320626 has no apparent structural relation
to any of the physiological compounds that bind to these
sites. To investigate how this and related compounds
bind to GP, we have determined the structure of the
cocrystallised rabbit muscle GPb–CP320626 complex.
The structure reveals a new allosteric site situated at the
dimer interface that has not been previously identified.
In order to compare the structural results obtained for
the muscle enzyme with the kinetic results reported for
the liver enzyme, we demonstrate through kinetic
studies that CP320626 has a similar potency on rabbit
muscle GP to that observed with the human liver and
muscle isoforms. 
Results and discussion
Effects of CP320626 on GPb activity
IC50 values for CP320626 inhibition of rabbit muscle
GPb without or with 10 mM glucose were 334 ± 10 nM
and 178 ± 10 nM, respectively. Hoover et al. [22] reported
IC50 values of 205 nM and 83 nM for CP320626 inhibi-
tion of human liver GPa and human muscle GPa, respec-
tively, in the presence of 0.5 mM glucose-1-P, 0.1%
glycogen and 7.5 mM glucose, in a buffer consisting of
50 mM HEPES (pH 7.2), 100 mM KCl, 2.5 mM EDTA,
2.5 mM MgCl2 at 22°C. The slightly different IC50 values
might be due to the different isoforms and different sub-
strate concentrations and assay conditions used. The rela-
tive potency of the inhibitor observed in our kinetic
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Figure 1
The chemical structures of (a) CP91149 and (b) CP320626, showing
the numbering system used.
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experiments (a factor of 1.9) without/with glucose is con-
sistent with the synergy observed previously with
CP911149 and glucose. Synergy with glucose confers an
additional benefit, allowing the effector to modulate its
effect in response to glucose concentrations.
CP320626-binding site
The overall architecture of the native T state GPb and
the catalytic and the allosteric sites have been described
previously [4] (Figure 2). The two subunits of the func-
tionally active dimer are related by a crystallographic
twofold symmetry axis and enclose a solvent-filled central
cavity surrounded on each side by residues from the 
N-terminal domains of both subunits. The structure of
the cocrystallised GPb–CP320626 complex has been
refined at 2.3 Å to a crystallographic R value of 0.199
(Rfree = 0.246) (Table 1). CP320626 binds in the central
binding cavity between the two subunits; this is the first
time a ligand has been reported to bind at this site. The
binding site is some 15 Å from the AMP allosteric effector
site, 33 Å from the catalytic site, and 37 Å from the caf-
feine inhibitor site.
The central cavity of T state GPb is ~30 Å long, with a
radius that varies from a maximum of ~8 Å to a minimum
of ~4 Å, and encloses a volume of 1300 Å3. The cavity is
partially closed at one end by residues from the cap and
α2 helices (Arg33, His34, Arg60 and Asp61 and their
symmetry-related equivalents) and at the other end by
the tower helices (residues Asn270, Glu273, Ser276 and
their symmetry-related equivalents; Figure 2). In the
2.0 Å resolution 100K T state GPb structure [15], 60
water molecules have been located in the cavity (30
water molecules from each subunit). These water mol-
ecules form few contacts with the protein: only four out
of the 30 make more than one hydrogen bond to protein
atoms. Nine water molecules present in the native T
state GPb structure become displaced on binding
CP320626, five from one subunit and four from the sym-
metry-related subunit.
The inhibitor becomes almost entirely buried on forming
the complex with GPb. The solvent accessibilities of the
free and bound CP320626 molecules are 643 Å2 and
107 Å2, indicating that a surface area of 536 Å2, respec-
tively, becomes inaccessible to water and that CP320626
becomes 83% buried in the enzyme complex. Binding of
CP320626 is associated with both subunits and nearly
equal surface areas from the two subunits are buried in
the inhibitor complex (307 Å2 from one subunit and
229 Å2 from the other). Both polar and nonpolar groups
are buried, but the greatest contribution comes from the
nonpolar groups, which contribute 457 Å2 (85%) of the
surface that becomes inaccessible. 
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Figure 2
A schematic diagram of the GPb dimer with
bound CP320626. One subunit is coloured
green and the other cyan. CP320626 is
shown in orange. (a) A view down the
molecular dyad showing the positions for the
catalytic site, allosteric effector site, and
CP320626-binding site together with the α2
helix and the cap′ region from the other
subunit. The catalytic site, marked by the
essential cofactor pyridoxal 5′-phosphate, is
buried at the centre of the subunit and is
accessible to the bulk solvent through a 15 Å
long channel that exits on the far side of the
molecule. Access to the site for bulky ligands,
such as glycogen, is blocked in the T state.
The inhibitor site (not shown), which binds
purine compounds such as caffeine, is
situated at the entrance to the catalytic site
tunnel. Occupation of this site stabilises the T-
state conformation of the enzyme and blocks
access to the catalytic site, thereby inhibiting
the enzyme in synergism with glucose at the
catalytic site. The allosteric site, which binds
the activator AMP, the weak activator IMP and
other phosphorylated compounds such as the
allosteric inhibitor glucose-6-P, is situated at
the subunit–subunit interface (between the
α2 and α8 helices of one subunit and cap′ of
the other subunit) some 30 Å from the
catalytic site. The CP320626-binding site,
located inside the central cavity between the
two subunits, is some 15 Å from the allosteric
effector site, 33 Å from the catalytic site and
37 Å from the inhibitor site. (b) A view, rotated
90° with respect to (a), normal to the twofold
axis. The CP320626-binding site and the
α2–cap′ interface are to the right and the
tower–tower′ subunit–subunit interface to the
left of the figure. The catalytic site is marked
by pyridoxal phosphate at the centre of each
subunit. Access to the catalytic site is via a
channel to the left of the figure.
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Interactions of CP320626 with protein residues
Views of the final electron-density map for the
GPb–CP320626 complex are shown in Figure 3. The
central C10 atom (with S stereochemistry) is tetrahedral
and the planes of the 5-choro-1H-indole ring, the fluo-
rophenylalanine ring and the 4-hydroxy-piperidyl ring are
almost mutually perpendicular. One carbonyl group, the
indolecarboxy carbonyl O1, is coplanar with the indole
ring and the other carbonyl group, the piperidyl carbonyl
O2, is approximately coplanar with the 4-hydroxy-
piperidyl. There are no intramolecular hydrogen bonds.
The 5-chloro-1H-indole ring binds to a pocket formed
mostly by one subunit whereas the fluorophenylalanine
ring binds to the walls of the central cavity and contacts
the other subunit, as shown in Figure 4a. 
The interactions of CP320626 with GPb involve six hydro-
gen bonds and 111 van der Waals contacts (within 4.0 Å),
47 of which are interactions between nonpolar groups
(Figure 4b; Tables 2 and 3). The 1H-indole-2-carboxam-
ide-binding pocket is formed by residues Arg60, Val64 and
Trp67 of the α2 helix, the loop residues Pro188, Trp189
and Glu190, Lys191 at the start of the short β7 strand,
Pro229 from strand β10 and Thr38′ and Val40′ of the cap′
region (where the prime refers to residues from the sym-
metry-related subunit). This part of the inhibitor exploits
numerous van der Waals contacts that are dominated by
the substantial contacts made to almost all atoms of Arg60.
The sidechain of Arg60 stacks against the 1H-indole-2-car-
boxamide group making some 23 van der Waals contacts.
The interaction of Arg60 on one side of the indole ring and
Lys191 on the other side involve interactions characteristic
of CH–pi interactions [23] between the hydrogen atoms of
the aliphatic carbons and the pi electrons of the aromatic
ring. The NE atom of the arginine is 3.4 Å from the ring
centre of the indole and there is scope for amino–aromatic
interactions, as observed in several protein–ligand com-
plexes [24] including complexes between the phosphoty-
rosine-recognition domain SH2 and phosphotyrosine
peptides [25]. The chlorine of the indole ring is buried in a
pocket where it makes van der Waals interactions to
Arg60, Val64 and Trp67 from adjacent turns of the α2
helix. There are hydrogen bonds from N1 of the indole
ring to the mainchain oxygen atom of Glu190, from the N2
of the carboxamide to the mainchain oxygen of Thr38′ and
a water-mediated hydrogen bond from the carbonyl O1 to
the mainchain nitrogen of Ala192. 
The 4-fluorobenzyl (or the fluorophenylalanine) moiety
makes 47 van der Waals contacts (20 nonpolar–nonpolar) to
residues that are all from the symmetry-related subunit.
The 4-fluorobenzyl and Phe53′ rings are inclined approxi-
mately 60° and there are extensive contacts between them
(Table 3). These contacts are augmented by nonpolar con-
tacts to the edge of His57′ and to residues Thr38′, Leu39′
and Pro188′. The fluorine atom makes 15 van der Waals
contacts and there are two polar contacts between the fluo-
rine atom and residues 187′ and 188′, a short contact with
the mainchain nitrogen atom of Pro188′ (2.8 Å) and a longer
contact with the mainchain nitrogen of Asn187′ (3.3 Å).
The 4-hydroxy-piperidyl moiety makes relatively few van
der Waals interactions with the protein and 11 out of 14
contacts are to water molecules in the central cavity.
There are three hydrogen bonds: a direct hydrogen bond
from piperidyl carbonyl O2 to Lys191 (NZ) and water-
mediated hydrogen bonds from the piperidyl N3 to
Ala192 (N) and from the 4-hydroxy-piperidyl O3 to the
OH of Tyr226. 
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Table 1
Diffraction data and refinement statistics for the T-state
GPb–CP320626 complex.
Space group P43212
Unit-cell dimensions 
a,b,c (Å) 129.2,129.2,116.2
No. of images (°) 32 (1°)#
Resolution range (Å) 30–2.3 Å
No. of observations 160,475 
No. of unique reflections 42,617
I/σ(I) (outermost shell)* 6.8 (1.7)
Completeness (outermost shell) (%) 96.3 (91.0)
Rmerge (outermost shell)† 0.110 (0.445)
Multiplicity 3.8
Outermost shell (Å) 2.34–2.30
Refinement (resolution) (Å) 30–2.3
No. of reflections used in refinement 40,437 
No. of reflections used for Rfree 2162 
Residues included 13–842
No. of protein atoms 6749
No. of water molecules 256
No. of ligand atoms 
PLP 15 
CP320626 32 
Final R (Rfree) (%)‡ 19.9 (24.6)
Rmsd in bond lengths (Å) 0.008
Rmsd in bond angles (°) 1.4
Rmsd in dihedral angles (°) 25.6
Rmsd in improper angles (°) 0.7
Average B factor (Å2) 13–842
for protein residues
overall 30.7 (27.1)§
CA,C,N,O 29.4 (25.8)§
sidechain atoms 32.0 (28.4)§
Average B (Å2) for ligands
PLP 17.1
CP320626 19.8
water molecules 33.8
*σ(I) is the standard deviation of I. †Rmerge = ΣιΣη | <Ih> — Iih | / Σι Ση
Iih, where <Iih> and ith are the mean and ith measurement of intensity
for reflection h, respectively. ‡Crystallographic R factor = Σ | |Fo| — |Fc |
| / Σ |Fo|, where |Fo| and |Fc| are the observed and calculated structure
factor amplitudes, respectively. Rfree is the corresponding R value for a
randomly chosen 5% of the reflections that were not included in the
refinement. § The average B factor (Å2) (given in parentheses) for
protein residues if the poorly defined residues were excluded. #1° is
the rotation range per image.
The 18 amino acid residues (nine from each subunit)
implicated in CP320626 binding are highly conserved in
GPs from human muscle, human liver, human brain, rat
muscle, rat liver and rat brain [26]. With the exception of
Ala192 (which is serine in the human liver isoenzyme), a
total of 17 residues that come into close contact with
CP320626 are identical in the rabbit muscle and human
liver GPs. This suggests that the site is likely to be the
same in the liver enzyme. 
Conformational changes
There are negligible changes in the mainchain conforma-
tion on binding of CP32026 to GPb, but there are shifts in
some residues surrounding the inhibitor. The superposition
of the structures of the native T state GPb and the
GPb–CP320626 complex over the well-defined residues
(16–208, 213–249, 261–313, 326–549 and 558–830) gave root
mean square (rms) deviations of 0.138, 0.151 and 0.351 Å for
Cα, mainchain and sidechain atoms, respectively, indicat-
ing that the two structures have very similar overall confor-
mations to within the limits of the resolution of the study.
The greatest changes involve shifts of the sidechain of
Arg60. In the native GPb structure, Arg60 restricts the
5-choro-1H-indole pocket, but in the GPb–CP320626
complex this residue shifts by ~1.3–3.5 Å in order to opti-
mise binding. There are also shifts of the sidechain atoms of
Val64 by ~2.0–2.2 Å, and shifts of the sidechain atoms of
Lys191 of ~0.6–1.3 Å that improve contacts with the chlo-
rine atom and the 4-hydroxy-piperidyl group, respectively.
There are no changes at the catalytic site, at the inhibitor
site or at the tower–tower′ helix subunit interface. 
In the native T state GPb structure, there are hydrogen
bonds across the subunit interface in the vicinity of the
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Figure 3
Stereo diagrams of the electron density of the
final weighted 2Fo–Fc map. (a) The
CP320626-binding site. (b) A close up of the
bound CP320626 molecule. The contour
level corresponds to approximately 1 root
mean square deviation calculated for the map. 
CP320626-binding site that are important for maintaining
the dimer structure [27]. Arg60 hydrogen bonds to the
mainchain oxygen of Phe37′ (2.9 Å), Arg193 hydrogen
bonds to the mainchain oxygens of residues Leu39′ (2.9 Å)
and Val40′ (2.9 Å) and Glu195 hydrogen bonds to Lys41′
(2.9 Å). On forming the complex with CP320626, the
major shift in Arg60 and the minor shifts in residues
39′–40′ cause the intersubunit hydrogen bond between
Arg60 and Phe37′ to be broken. However, the intersub-
unit hydrogen-bonding pattern between residues 193 and
195 and residues 39′ and 40′ is not significantly changed.
The hydrogen bonds of Arg193 to the mainchain oxygen
of Leu39′ (3.4 Å) and Val40′ (3.4 Å) are weakened, but
Glu195 is still able to hydrogen bond to Lys41′ (2.9 Å).
The Tyr185′–Pro194 contact, which is an important
subunit–subunit contact and a major link between the
cap′–α2 helix and the tower–tower′contacts [28], is also
retained in the GPb–CP320626 complex.
Comparison with GPa in the R state
Liver GP is controlled mostly by the phosphorylation/
dephosphorylation of Ser14 and is much less responsive
than the muscle enzyme to allosteric effectors such as
AMP [3]. Modelling studies on the liver isoform suggest
that the two enzymes, which are 80% identical in
sequence, are likely to have very similar structures,
although there may be some differences at the
tower–tower′ subunit interface [16]. These differences do
not affect the CP320626-binding site as discussed above. It
is, therefore, of interest to compare the CP320626-binding
site in GPb and GPa as this might help us to understand
the basis for inhibition and synergy with glucose.
The conversion of the less active T state muscle GPb to
the active R state GPa involves changes in the tertiary and
quaternary structure [29–32]. In the R state, relative to the
T state, one subunit is rotated relative to the other by 9.6°
so as to bring the two subunits closer together at the
α2′–cap interface and causing them to move further apart
at the tower–tower′ interface of the dimer. The contacts at
the α2–cap′ interface are increased either by the contacts
to the Ser14 phosphate or by contacts to the allosteric
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Figure 4
Details of the CP320626-binding site. (a) Close-up view of the
central cavity showing the CP320626 allosteric binding site in the
same orientation and colour scheme as Figure 2a. The Cα positions
of certain key residues mentioned in the text are labeled (Arg60,
Val64, Lys191, Thr38′, Val40′, His57′, Tyr185′ and Pro188′). The
C-terminal tail, with the C-terminal residue 842 labeled, is visible in
the lower right. The shortest and longest distances between the two
symmetry-related CP320626 molecules when bound to GPb are
5.6 Å (C13–C13′) and 12.8 Å (O2–O2′), respectively. (b) Details of
the interactions between CP320626 and GPb shown in stereo. The
chloroindole-binding pocket is in the lower part of the figure and the
fluorophenylalanine-binding pocket in the upper part. The view is the
same as in (a). Hydrogen bonds are shown as thin lines.
Table 2
Hydrogen bonds* between CP320626 and GPb.
Inhibitor atom Protein atom Distance (Å)
N1 Glu190 O 2.9
O1 Wat159 3.2
N2 Thr38′ O 2.9
O2 Lys191 NZ 2.9
N3 Wat159 3.0
O3 Wat92 3.0
*Hydrogen-bonds were assigned if the distance between the
electronegative atoms was less than 3.3 Å and if both angles between
these atoms and the preceding atoms were greater than 90°. Wat92 is
hydrogen bonded to Tyr226 OH (3.1 Å) and to Wat158 (3.2 Å);
Wat158 is in turn hydrogen bonded to Glu190 OE1 (2.8 Å); Wat159
is hydrogen bonded to Ala192 N (2.5 Å) and to Wat158 (2.9 Å).
effector AMP. The movements at the tower–tower′ inter-
face lead to displacement of a loop (the 280s loop) that
blocks the access of large ligands such as glycogen to the
catalytic site. Displacement of this loop removes an acidic
residue (Asp283) from proximity with the 5′-phosphate of
the cofactor pyridoxal phosphate and allows replacement
of the acidic residue by a basic residue (Arg569) that
creates an anion recognition site for the phosphate sub-
strate. Thus changes at the subunit interfaces are closely
coupled to changes at the catalytic site.
Comparison of the T state GPb–CP320626 complex with
R state GPa [31] shows that the ligand-binding site is
likely to have considerably lower affinity in GPa. Super-
position of the structure of the R state GPa (subunit A)
with the structure of the GPb–CP320626 complex gave
rms deviations of 1.201, 1.213 and 2.028 Å for Cα, main-
chain and sidechain atoms, respectively, for ordered
residues 16–208, 213–249, 261–313, 326–549 and
558–830. In GPa the CP320626-binding site is squeezed
at the 5-chloro-1H-indole pocket and is more open at the
fluorophenylalanine site as a consequence of these
changes in tertiary and quaternary structure (Figure 5).
The conformational changes in the α2 helix lead to a
more perfect α helix in GPa and the Cα atoms of Arg60
and Val64 are 0.7 Å closer in GPa than in GPb (Figure
5a). The sidechains of residues Arg60 and Lys191 would
be required to move in order to open up the site, as
indeed they do on forming the GPb–CP320626 complex,
but the close contact between the sidechain of Val64 and
CP320626 would be difficult to relieve when the α2 helix
is locked in the R-state conformation. At the fluo-
rophenylalanine site, the shift in the symmetry-related
subunit by ~2 Å results in the loss of contacts to Phe53′
and Tyr185′ (Figure 5b). The changed shape of the
cavity between GPb and GPa shows that the T-state con-
formation favours binding of CP320626 whereas the R
state does not. Conversely, binding of CP320626 will
shift the equilibrium between the R and T states in
favour of T state.
Potency and selectivity
The structure of the GPb–CP320626 complex pinpoints
specific interactions responsible for the high affinity and
selectivity of CP320626 for the enzyme. On binding to
GPb, CP320626 exploits numerous van der Waals con-
tacts that are dominated by the substantial nonpolar con-
tacts to the aliphatic parts of Arg60 and Lys191, to Val64,
to the edge atoms of Trp67 and Pro229, and to Thr38′,
Leu39′, Val40′, Phe53′, His57′ and Pro188′ from the sym-
metry-related subunit (Figure 4; Table 3). These contacts
comprise aromatic–aromatic interactions (4-fluorobenzyl
group–Phe53′ sidechain), amino–aromatic interactions
(His57′–4-fluorobenzyl group; Arg60–indole ring), CH–pi
electron interactions (Arg60 sidechain–indole ring;
CE3 and CZ3 of Trp67–indole ring; CG and CD of
Pro229–indole ring; Val40′ sidechain–indole ring; CA, CB
and CD of Pro188′–4-fluorobenzyl group), and non-
polar–nonpolar interactions (CB of Ala192–C15 of the
piperidyl group; CG2 of Thr38′–C17; and CD1 of
Leu39′–C17). All of the polar groups on CP320626 are
involved in hydrogen bonds either directly with the
protein or through water molecules. The increase in
entropy from the release of nine water molecules at the
binding site, together with the van der Waals, CH–pi,
halogen–polar, and the specific polar–polar interactions
appear to be the major source of binding energy that
results in an inhibitor with high affinity for GPb. The
contacts between GPb and CP320626 are remarkable
because the enzyme has no biological reason to recognise
this ligand. 
Kinetic experiments [22] show that the 1H-indole-2-car-
boxamide moiety is an important determinant of selectiv-
ity in the two series of inhibitors derived from
3-((indole-2-carbonyl)amino)-2-hydroxy-4-phenyl-butyric
acid and N-(indole-2-carbonyl)phenylalanine. The
1H-indole-2-carboxamide group binds in a pocket filled
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Table 3
Van der Waals contacts* between CP320626 and GPb.
Inhibitor atom Protein atom No. of contacts
CL1 Arg60 O, CG; Val64 N, CA, CB; Trp67 CE3 6
C1 Arg60 CG, NE, CD; Trp67 CE3, CZ3; Val40′ CG2 6
C2 Arg60 CG, CD; Trp67 CZ3; Pro229 CG, CD 5
C3 Arg60 CD; Pro188 O; Trp189 O, C 4
C4 Arg60 NE, CD, CZ; Pro188 O; Glu190 O; Lys191 CB 6
N1 Arg60 CZ; Pro188 O; Glu190 C; Lys191 N, CA, CB 6
C5 Arg60 NE, CD, CZ, NH1; Val40′ CG2 5
C6 Arg60 CG, NE, CD; Val40′ CG2; Wat248 5
C7 Arg60 NE, CZ, NH1; Thr38′ O; Val40′ CG2 5
C8 Arg60 CZ, NH1; Glu190 O; Lys191 CD 4
C9 Thr38′ O 1
O1 Glu190 O 1
C10 Thr38′ O 1
C11 Wat159 1
O2 Lys191 CD, CE 2
C12 Wat159 1
C13 Wat158; Wat159 2
C14 Gly186′ CA; Wat92 2
O3 Gly186′ CA 1
C15 Ala192 CB; Tyr185′ O; Wat159; Wat247 4
C16 Wat159; Wat247 2
C17 Thr38′ O, CG2; Leu39′ CD1 3
C18 His57′ CE1, NE2 2
C19 His57′ CE1, NE2; Wat223′ 3
C20 His57′ CE1, NE2; Pro188′ CA,CB 4
C21 Phe53′ CD2, CE2; His57′ CE1; Pro188′ N, CA, CB, CD 7
F1 Phe53′ CD2, CE2, CZ; Gly186′ O, C, CA; 
Asn187′ O, N, C, CA; Pro188′ CA, CB, N, CG, CD 15
C22 Phe53′ CG, CD2, CE2,CZ; His57′ CE1 5
C23 Leu39′ CD1; His57′ CE1 2
Total 111
*Van der Waals interactions were assigned for non-hydrogen atoms
separated by less than 4 Å.
by close-packed sidechains and opening of this pocket
requires a conformational change, mainly at the level of
the sidechain of Arg60. The structure-activity relation-
ships showed that changing the indole-5-substituent in
the phenylalanine series reduced inhibitory activity in the
order Cl ~ Br > F ~ H >OCH3. Our structural results
suggest that the Cl substituent does not fully occupy the
space available and that there is enough space to accom-
modate Br, whereas substitution of the indole-5 with
OCH3 would result in a steric clash of the inhibitor with
protein residues. Hydrogen bonding between N1 (-NH)
of the indole ring and the mainchain oxygen of Glu190
appears to be important in enhancing the affinity of
CP320626 for the enzyme. Substitution of N1 of the
indole ring with N-CH3, in N-methylindole, or with
oxygen, in benzofuran, affects ligand affinity. Thus, for
both compounds, the IC50 increases from 205 nM (with
respect to human liver GPa) to >10,000 nM [22]. These
differences in the IC50 values can be attributed to the lack
of a hydrogen bond between the N1 atom and mainchain
oxygen of Glu190 in the latter derivatives.
Mechanism of inhibition
The structural results show that the CP320626-binding
site in GPb provides a bridge between the subunits.
Although the small conformational changes in tertiary
structure on forming the complex result in the loss of one
hydrogen bond from Arg60 to the other subunit, the
extensive nonpolar contacts and the six hydrogen bonds
from the inhibitor to the protein strengthen the
subunit–subunit interface and lock it in a conformation
close to the T-state quaternary conformation. Thus,
CP320626 acts as an allosteric inhibitor binding at a site
distant from the catalytic site and exerting its effects by
promoting the T-state conformation, consistent with the
Monod–Wyman–Changeux [33] model for allosteric
effects. Glucose binds more tightly to T-state GP making
contacts to the 280s loop in the closed T-state conforma-
tion at the catalytic site. Therefore, by promoting the T
state, CP320626 will also promote synergistic glucose
binding. The CP320626 site is remote from both the AMP
and Ser14 phosphate binding sites but all three sites make
contacts to residues in two key regions of the
protein — the α2 helix and the cap′ region of the other
subunit. By tuning these contacts, effectors may promote
either the T state or the R state. The result is reminiscent
of that observed for the four novel potent allosteric
inhibitors of hemoglobin: bezafibrate, LR16, L35, L345
and related compounds [34,35]. The binding sites of these
inhibitors lie in the central water cavity, mainly between
the α chains; the sites are distant from the allosteric 
2,3-bisphosphoglycerate-binding site. 
582 Structure 2000, Vol 8 No 6
Figure 5
GPa in the R state viewed in a similar orientation to that of the
GPb–CP320626 complex in Figures 2 and 4; the position of
CP320626 is superimposed. (a) Close-up view of the CP320626 site
in GPa with the Cα positions of residues shown in Figure 4a labeled.
In R state GPa, the N-terminal tail containing the Ser14 phosphate
group (lower right) displaces the C-terminal tail of GPb. The α2 helix
adopts a more perfect helix in GPa compared with GPb and residues
60 and 64 are 0.7 Å closer together, thus squeezing the chloroindole-
binding site. As a result of quaternary and tertiary structural changes,
the loop comprising residues 185′–188′ and the α2′ helix from the
other subunit shift ~2 Å so that the fluorophenylalanine site is more
open. (b) Details of the CP320626 site in GPb, as in Figure 4b, with
residues from GPa superimposed and shown in white. Some residues
shown in Figure 4b have been omitted for clarity. The shifts in Arg60,
Val64 and Lys191 in GPa block the chloroindole site as indicated by
the two white convergent arrows. The shifts in residues 185′–188′ and
Phe53′ (shown by the white arrow at the top) result in an open site at
the fluorophenylalanine-binding site in GPa. 
Biological implications
Type 2 diabetes is a prevalent disease that affects about
4–5% of the population. There is a continued search for
compounds that can improve therapy. Liver glycogen
phosphorylase (GP) has been identified as a possible
target for drugs that control blood glucose concentra-
tions. There are two forms of GP: the phosphorylated
form (GPa) and the dephosphorylated form (GPb). In
both forms, allosteric effectors can promote equilibrium
between a less active T state and a more active R state. 
A data bank search led to the identification of the com-
pound 5-chloro-1H-indole-2-carboxylic acid (1-(4-fluo-
robenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl)amid
e (CP320626) as a potent inhibitor of GP. CP320626
shows no structural similarity to any natural regulators
of phosphorylase activity. The crystallographic binding
studies reported here with T state rabbit muscle GPb
show that CP320626 occupies a buried site in the
central cavity of the dimeric enzyme. The inhibitor
makes extensive contacts between residues from both
subunits and all but one of these residues are conserved
in human liver GP, indicating that this site is the proba-
ble site of action in the liver enzyme. The contacts
between CP320626 strengthen the subunit–subunit
interface of the T-state conformation. The tertiary and
quaternary structural changes that occur between the
T-state and R-state phosphorylase result in subtle but
significant changes at this subunit–subunit interface and
a less favourable binding site in the R state. The struc-
ture highlights the importance of protein–protein inter-
face interactions in oligomeric allosteric proteins. By
binding at a site remote from the catalytic site and other
effector sites, CP320626 is nevertheless able to influence
catalytic activity by promoting the less active T-state
conformation over the active R-state conformation. The
structure reveals a new allosteric binding site for modu-
lating activity that might prove of practical importance
in the structure-based design of new inhibitors with
improved pharmacological properties. 
Materials and methods
Kinetic experiments
Rabbit muscle GPb was isolated, purified, freed of AMP and assayed
as described [36] with minor modifications. The enzyme (5 µg ml—1)
was assayed at pH 6.8 and 30°C with 10 mM glucose-1-P, 1% glyco-
gen and 1 mM AMP in 50 mM triethanolamine hydrochloride, 100 mM
KCl, 1 mM EDTA, 1 mM DTT buffer, and 1% DMSO. The enzyme was
preincubated with glycogen and a range of concentrations of
CP320626 for 60 min at 30°C before the reaction was started by
adding glucose-1-P. CP320626 was synthesised by MercaChem
(Nijmegen, The Netherlands), according to the procedures described
by Hoover et al. [22].
Crystallisation and data collection
The GPb–CP320626 complex was cocrystallised under conditions
similar to those described previously [20]. Just before data collection,
the crystals were transferred to a fresh buffer solution (3 mM DTT,
10 mM BES, 0.1 mM EDTA, 0.02% sodium azide, pH 6.7). There were
only small changes in unit-cell dimensions on complex formation, result-
ing in volume changes of 1.0% compared with native crystals [27].
Data were collected from a single crystal using a rotating anode source
(λ = 1.5418 Å) and an 18 cm small Mar detector. Crystal orientation,
integration of intensities and data reduction were performed using
DENZO and SCALEPACK [37].
Structure refinement
Crystallographic refinement of the GPb–CP320626 complex was per-
formed with X-PLOR version 3.8 [38] using bulk-solvent corrections. All
data between 30.0 and 2.3 Å were included with no sigma cut-off. The
starting protein structure was the refined model of the room tempera-
ture GPb–glucose complex [39], with water molecules removed. The
Fourier maps calculated with SIGMAA-weighted [40] (2mFo–DFc) and
(Fo–Fc) coefficients indicated tight binding of CP320626 at a site not
previously characterised and located in the region of the central cavity
of the dimer. A model of CP320626 generated using the program
SYBYL [41] was fitted to the electron-density map after torsion angles
of the computed model were adjusted. Map interpretation was per-
formed using the program O [42]. Several sidechains of the enzyme
model were adjusted and water molecules were added to the atomic
model and retained only if they met stereochemical requirements by
using WATERPICK (in X-PLOR). The final model was refined by the
conventional positional and restrained individual B-factor refinement
protocol in X-PLOR to give a final R factor value of 19.9%
(Rfree = 24.6%). The structure contained residues 13–842 and
256 water molecules. A Luzatti plot [43] determined using the X-PLOR
protocol suggests an average positional error of ~0.25 Å. Residues
where B-factor values of mainchain atoms exceed 60 Å2 include 13–15
(71.8 Å2), 209–212 (67.1 Å2), 250–260 (91.4 Å2), 314–325 (90.6 Å2),
550–557 (76.0 Å2) and 831–842 (87.1 Å2). The same regions are also
poorly ordered in the native enzyme structure. The model displays good
stereochemistry as determined by PROCHECK [44] with 86.3% of
residues in the most favoured regions, 10.6% in the additional allowed
regions, 2.3% in the generously allowed regions and 0.8% of residues
(Val259, Ser314, Arg319, Arg323, His556 and Lys840 of the most
disordered regions of the protein) in the disallowed regions. A summary
of the data processing statistics and refinement parameters for the
GPb–CP320626 complex structure is given in Table 1. Volumes were
calculated with the program VOIDOO [45] and solvent accessibilities
were calculated with the program NACCESS [46].
Structure comparisons
GP structures were superimposed over well-defined residues using
LSQKAB [47] and subunit rotations were determined following the
method of Sprang et al. [32]. Structural units (N-domain core, C-domain
core and activation locus) were those defined previously. The major shifts
between the GPb–CP320626 complex and native GPb for Cα atoms
are for residues 38′ to 46′ of the symmetry-related subunit (between
0.4–0.6 Å) from the cap′ region, residues 47′ to 75′ (between 0.5–0.8 Å)
from the α2 helix, and residues 184′ to 196′ (between 0.4–0.6 Å) from
the loop following the β6 strand and from the short  strand β7. These
shifts affect the subunit–subunit interface in the region between the cap′,
α2 helix and the loop between strands β7 and β8 of the symmetry-
related subunit. Coordinate sets used for  the comparison were: T state
GPb [27] (Protein Data Bank [PDB] ID code 1gpb), T state
GPb–glucose complex [39] (ID code 2gpb), T state 100K GPb [15] (ID
code 2gpn), R state GPa [31] (ID code 1gpa), and PLPP–GPb–AMP
[32] (ID code 1pyg). Figures 2–5 were produced using XOBJECTS, a
molecular illustration program (MEM Noble, unpublished results).
Accession numbers
The coordinates for the T state GPb–CP320626 complex have been
deposited with the PDB, Brookhaven National Laboratory, Upton, NY
11973 (accession code 1C50). 
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